2021-11-02T10:57:31-05:00 2020-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2020-01-01 911893957 THE MAX FOUNDATION MAXF 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 4257788660 2021-10-29 1 PATRICIA PEARCE 999009999 JENNIFER BECKER HARRIS P00183358 4254544919 2021-10-29 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z PATRICIA M PEARCE 1107 NE 45TH NO 230 SEATTLE WA 98105 10351422 0 X WWW.THEMAXFOUNDATION.ORG X 1997 WA AT THE MAX FOUNDATION, WE BELIEVE ALL PEOPLE LIVING WITH CANCER DESERVE ACCESS TO THE BEST TREATMENT, CARE, AND SUPPORT. WE ACCELERATE GLOBAL HEALTH EQUITY BY CHANNELING HUMANITARIAN DONATIONS OF LIFE-SAVING CANCER TREATMENTS TO UNDERSERVED POPULATIONS IN COUNTRIES WHERE THOSE PRODUCTS ARE NOT LOCALLY AVAILABLE. 9 8 21 567 0 0 57006075 6430918 3013178 3908320 -37995 -387 -63899 10 59917359 10338861 45642020 22805247 0 0 2281642 2576929 0 0 568431 2066078 1875661 49989740 27257837 9927619 -16918976 20037868 3335898 388552 605558 19649316 2730340 X AT THE MAX FOUNDATION, WE BELIEVE ALL PEOPLE LIVING WITH CANCER DESERVE ACCESS TO THE BEST TREATMENT, CARE, AND SUPPORT. AS SUCH, WE ACCELERATE GLOBAL HEALTH EQUITY BY CHANNELING HUMANITARIAN DONATIONS OF LIFE-SAVING CANCER TREATMENTS TO UNDERSERVED POPULATIONS IN COUNTRIES WHERE THOSE PRODUCTS ARE NOT LOCALLY AVAILABLE. 0 0 25429025 22805247 3908320 A KEY FOCUS OF THE ORGANIZATION IS EXPANDING HUMANITARIAN ACCESS TO INNOVATIVE TREATMENTS FOR CANCER IN LOW- AND MIDDLE-INCOME COUNTRIES. DONATIONS OF ONCOLOGY PRODUCTS FROM DRUG MANUFACTURERS ARE RECEIVED BY OUR SUPPORT ORGANIZATION, MAXAID, AND DISTRIBUTED TO INDIVIDUAL PATIENTS VIA OUR NETWORK OF HEALTHCARE PROVIDERS AND CANCER TREATMENT CENTERS. THIS ACCESS TO MEDICINES IS ENABLED THROUGH OUR PATIENT-CENTERED TREATMENT ACCESS MODEL KNOWN AS MAX ACCESS SOLUTIONS. OUR PRIMARY CLIENT IS A PATIENT WHO IS TREATED BY ONE OF OUR PARTNER PHYSICIANS, DIAGNOSED WITH A SPECIFIC CANCER, AND PRESCRIBED A MEDICATION FOR WHICH THE ONLY AVAILABLE FORM OF ACCESS IS A HUMANITARIAN CHANNEL THROUGH MAX ACCESS SOLUTIONS. WE USE A SOPHISTICATED WEB-ENGINE PLATFORM DEVELOPED IN-HOUSE TO ALLOW US TO WORK IN REAL TIME WITH HEALTHCARE PROVIDERS AND CREATE INDIVIDUALIZED PROGRAM LIFE CYCLES TO MEET EACH PATIENT'S NEEDS. WE FURTHER ACT AS HEALTHCARE NAVIGATORS FOR THESE PATIENTS, HELPING THEM WALK THROUGH THE ACCESS PROGRAM ENVIRONMENT. IN ORDER TO OPTIMIZE TREATMENT, WITHIN OUR CAPABILITIES WE PROVIDE WRAPAROUND SUPPORT THAT INCLUDES ACCESS TO DIAGNOSTIC TESTING, EMOTIONAL AND LOGISTICAL SUPPORT, INFORMATION RESOURCES AND EDUCATION, AS WELL AS ADVOCATING ON THEIR BEHALF WHEN NEEDED. WE ALSO STRENGTHEN THE COMMUNITIES AROUND PATIENTS BY SUPPORTING PATIENT ORGANIZATIONS AND CREATING AWARENESS INITIATIVES IN LOCAL AND GLOBAL COMMUNITIES. 25429025 1 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 1 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 1 1 1 1 0 0 1 X 9 0 21 1 0 1 IN MY TH AR SF 0 0 0 0 0 0 0 0 0 0 X 9 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA HI NY X X PATRICIA M PEARCE 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PATRICIA GARCIA-GONZALEZ CHIEF EXECUTIVE OFFICER 50.00 5.00 X X 234270 0 14560 PATRICIA M PEARCE CHIEF FINANCIAL OFFICER 40.00 2.00 X 186964 0 12490 CRAIG ANDERSON DIRECTOR OF IT 40.00 0.00 X 119245 0 15910 WILMA COMENAT VICE PRESIDENT, DEVELOPMENT 40.00 2.00 X 126513 0 7936 NEAL PARRY SENIOR SUPPLY CHAIN MANAGE 40.00 0.00 X 116424 0 12270 MICHAEL WRIGGLESWORTH SR. DIRECTOR OF PROGRAMS STRATEGY 40.00 0.00 X 125896 0 89 PAULA BOULTBEE BOARD PRESIDENT 5.00 2.00 X X 0 0 0 TRACEY HIGGINS BOARD VICE PRESIDENT 5.00 2.00 X X 0 0 0 CURT MALLOY BOARD SECRETARY 5.00 2.00 X X 0 0 0 JERRY SCOTT BOARD TREASURER 5.00 2.00 X X 0 0 0 MIKA MATSUZAKI BOARD MEMBER 5.00 2.00 X 0 0 0 JERALD JERRY RADICH MD BOARD MEMBER 5.00 2.00 X 0 0 0 SUSAN JERIAN BOARD MEMBER 5.00 2.00 X 0 0 0 GRANT RUBENSTEIN BOARD MEMBER 5.00 2.00 X 0 0 0 909312 0 63255 6 0 1 0 TANNERGAP INC 1808 ASSOCIATES LANE STE A CHARLOTTE NC 28217 SUPPLY CHAIN MANAGEMENT 458239 ANGEL KAUSHISH B-11 FLAT 1 MEERA NAGAR TERRACE LN PUNE MAHARASHTRA IN DATA SOLUTIONS DEVELOPER 125945 2 6430918 5859336 6430918 PATIENT CARE 624100 3742250 3742250 MEDICAL TEST KITS 624100 166070 166070 3908320 14 14 10 10 12160 0 12165 396 -5 -396 -401 -401 10338861 3908320 0 -377 10000 10000 22795247 22795247 448284 124657 261299 62328 55444 55444 1781132 942131 453070 385931 141802 73690 37794 30318 150267 72273 47666 30328 1974 1974 86160 86160 55778 39764 16014 237183 78923 138808 19452 85607 30925 47060 7622 161979 58516 89041 14422 37095 37036 29 30 82730 33787 30943 18000 50523 50523 COUNTRY REPRESENTATIVES 600367 600367 DISTRIBUTION & SHIPPING 476265 476265 27257837 25429025 1260381 568431 756835 1258331 60155 62455 50000 90000 505852 16245 16760380 137551 58020 73312 514210 227188 315850 287022 1530776 1410982 20037868 3335898 269769 209483 118783 99703 0 296372 388552 605558 X 2393700 1026770 17255616 1703570 19649316 2730340 20037868 3335898 -16918976 0 X X 0 1 X 1 0 X 13925957 18308593 27791248 57006075 6430918 123462791 13925957 18308593 27791248 57006075 6430918 123462791 106749778 16713013 5680 5434 4483 25 24 15646 4968 3693 1022 18869 0 28552 123506989 15344165 0.13530 0.13990 X 0.13990 THE MAX FOUNDATION QUALIFIES AS A PUBLICLY SUPPORTED CHARITY UNDER THE FACTS AND CIRCUMSTANCES EXCEPTION PROVIDED TO IRC SECTION 509(A)(1) CHARITIES UNDER TREAS. REG. SEC. 1.170A-9(E)(3). THE FOUNDATION DOES NOT RECEIVE AT LEAST ONE THIRD OF ITS SUPPORT FROM THE PUBLIC. IT DOES HOWEVER MEET THE TESTS REQUIRED UNDER THE FACTS AND CIRCUMSTANCE TEST: I. THE FOUNDATION NORMALLY MEETS THE PUBLIC SUPPORT TEST AS PROVIDED IN THE REGULATIONS. THE AGGREGATE PUBLIC SUPPORT PERCENTAGE FOR THE YEARS ENDED DECEMBER 31, 2019, 2018, 2017, AND 2016 IS 17.27%, 27.73%, 41.45%, AND 30.50% RESPECTIVELY. II. THE FOUNDATION CARRIES ON A BONA FIDE CONTINUOUS PUBLIC SOLICITATIONS PROGRAM. ITS FUNDRAISING EFFORTS INCLUDE ANNUAL MAILINGS TO SOLICIT FUNDS, PUBLISHING OF AN ANNUAL REPORT TO EDUCATE ITS DONOR BASE AND FURTHER SOLICIT DONATIONS, AND OTHER FUNDRAISING ACTIVITIES. IN 2020 THE FOUNDATION WAS UNABLE TO HOLD ITS ANNUAL FUNDRAISING GALA, DUE TO COVID-19 SOCIAL DISTANCING RESTRICTIONS. THE 2019 GALA HAD RAISED NEARLY $143,000 WHICH WAS A MARKED INCREASE FROM OUR 2017 FIRST GALA WHICH RAISED OVER $98,000. HOWEVER, IN 2020 A NEW PEER-TO-PEER CAMPAIGN WAS LAUNCHED, MAX-A-THON, WHICH RAISED CLOSE TO $40K. IN 2017 AND 2018 WE ALSO HAD INTERNATIONAL FUNDRAISING EVENTS CALLED MAX GLOBAL EXPERIENCE WHICH RAISED OVER $109,000 AND OVER $80,000, RESPECTIVELY, FROM THE GENERAL PUBLIC. SINCE 2017 FIVE MULTINATIONAL PHARMACEUTICAL COMPANIES JOINED THE FOUNDATION IN WHAT WE CALL A HUMANITARIAN PARTNERSHIP FOR ACCESS TO CANCER TREATMENT (PACT). THROUGH THESE HUMANITARIAN COLLABORATIONS, EACH COMPANY HAS COMMITTED TO DONATE PRESCRIBED MEDICATIONS FOR A DIFFERENT NUMBER OF PATIENTS WITHIN THEIR CAPABILITIES, AND ALL HAVE COMMITTED THEIR SUPPORT FOR AS LONG AS EACH PATIENT NEEDS IT. III. DURING THE YEARS ENDED DECEMBER 31, THE FOUNDATION HAD THE FOLLOWING SUPPORTERS, RESPECTIVELY: 2015: INDIVIDUALS-307CORPORATIONS- 8FOUNDATIONS - 1 TOTAL-3162016:INDIVIDUALS - 371 CORPORATIONS - 24 FOUNDATIONS - 2TOTAL - 3972017:INDIVIDUALS - 676 CORPORATIONS - 35 FOUNDATIONS - 2TOTAL - 7132018:INDIVIDUALS - 377 CORPORATIONS - 42 FOUNDATIONS - 2TOTAL - 4212019:INDIVIDUALS - 183CORPORATIONS - 35FOUNDATIONS - 0TOTAL - 2182020:INDIVIDUALS - 245CORPORATIONS - 34FOUNDATIONS - 2TOTAL - 281IV. THE PUBLIC NATURE OF THE FOUNDATION'S GOVERNING BOARD -- THE FOUNDATION HAS A BOARD OF DIRECTORS THAT INCLUDES PROFESSIONALS, COMMUNITY LEADERS, AND OTHER PERSONS WITH EXPERTISE IN DIFFERENT DISCIPLINES. IN ADDITION, THE FOUNDATION HAS A MEDICAL ADVISORY BOARD AND A STRATEGIC INNOVATION ADVISORY BOARD. OUR MEDICAL ADVISORY BOARD INCLUDES SPECIALISTS WHO ARE KEY OPINION LEADERS IN THE FIELD OF ONCOLOGY AND HEMATOLOGY. BASED ALL AROUND THE WORLD THESE EXPERT PHYSICIANS ARE FORMATIVE IN LEADING RESEARCH AND MANAGING PATIENT CARE AT THEIR CENTERS OF EXCELLENCE. OUR STRATEGIC INNOVATION ADVISORY BOARD HAIL FROM BOTH THE PUBLIC AND PRIVATE SECTORS AND INCLUDE GLOBAL LEADERS FROM THE FIELD OF GLOBAL HEALTH, FUNDRAISING, BUSINESS, AND COMMUNICATIONS. V. THE FOUNDATION SUPPORTS GLOBAL HEALTH EFFORTS BY:-- CREATING ACCESS CHANNELS TO INNOVATIVE CANCER MEDICINES FOR PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES WHERE NO OTHER MEANS OF ACCESS EXISTS, -- MAKING TREATMENT, CARE, AND SUPPORT AVAILABLE IN LOW- AND MIDDLE- INCOME COUNTRIES AND THEREBY PREVENTING AVOIDABLE CANCER DEATHS AROUND THE WORLD,-- CREATING A MODEL THAT ENABLES THE PRIVATE SECTOR TO HELP CANCER PATIENTS IN NEED,-- STRENGTHENING HEALTH SYSTEMS AND LOCAL SUPPORTS THROUGH WRAPAROUND SERVICES FOR PATIENTS AND THEIR COMMUNITIES.VI. MAX ACCESS SOLUTIONS IS THE FOUNDATION'S OPERATIONAL PROGRAM THROUGH WHICH HUMANITARIAN DONATIONS OF APPROVED ONCOLOGY PRODUCTS ARE CHANNELED TO PATIENTS IN NEED. MAX ACCESS SOLUTIONS IS DESIGNED TO BE A BRIDGE FOR ACCESS TO TREATMENT SPECIFICALLY WITHIN LOW- AND MIDDLE-INCOME COUNTRIES WHERE THE BURDEN OF DISEASE IS HIGH AND LOCAL GOVERNMENT ACCESS PROGRAMS MAY NOT BE CURRENTLY FEASIBLE.WITHIN MAX ACCESS SOLUTIONS, COMPANIES DONATE PRODUCT TO THE FOUNDATION AND THE ORGANIZATION CHANNELS PRODUCT AT ITS DISCRETION TO PATIENTS IN NEED THROUGH THEIR TREATING PHYSICIAN AND WITHIN THE SCOPE OF ITS COLLABORATION AGREEMENTS. VETTED HEALTH CARE PROVIDERS IN LOW- AND MIDDLE-INCOME COUNTRIES INITIATE THE PRODUCT REQUEST AND MANAGE TREATMENT OF PATIENTS RECEIVING PRODUCT FROM THE FOUNDATION. THE FOUNDATION WORKS THROUGH A THIRD-PARTY LOGISTICS PROVIDER WHO, AS ITS AGENT, RECEIVES PRODUCT FROM MANUFACTURERS AND SHIPS IT TO END USERS ON THE ORGANIZATION'S BEHALF.AT THE CENTER OF OUR MODEL IS A PATIENT WHO HAS BEEN DIAGNOSED WITH CANCER BY ONE OF OUR PARTNER PHYSICIANS AND PRESCRIBED A TREATMENT IN OUR PORTFOLIO FOR WHICH NO LOCAL ACCESS EXISTS. WORKING IN COLLABORATION WITH A ROBUST NETWORK OF LEADING CANCER TREATING INSTITUTIONS AND PHYSICIANS, DRUG MANUFACTURERS, AN INTERNATIONAL DISTRIBUTOR, AND LOCAL PATIENT SUPPORT ORGANIZATIONS, WE PROVIDE HUMANITARIAN ACCESS TO THE TREATMENT WITH THE AIM THAT EACH REQUIRED DAILY DOSE REACHES THE INTENDED PATIENT AT THE RIGHT TIME, WHILE STRENGTHENING THE LOCAL HEALTHCARE SYSTEM.IN 2020, THE FOUNDATION PROVIDED SERVICES TO 33,542 INDIVIDUAL CANCER PATIENTS IN 73 COUNTRIES INCLUDING DELIVERING 8.1 MILLION DAILY DOSES OF CRITICAL CANCER TREATING MEDICATION, PROVIDING 5,000 MOLECULAR DIAGNOSTIC TESTS, AND ORGANIZING AND DELIVERING 28 AWARENESS EVENTS AND ONLINE PATIENT EDUCATION SESSIONS, IN PARTNERSHIP WITH A GLOBAL NETWORK OF 380 MEDICAL INSTITUTIONS AND 536 DOCTORS. SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2016 AMOUNT: $ 4,968. 2017 AMOUNT: $ 3,693. 2018 AMOUNT: $ 1,022. 2019 AMOUNT: $ 18,869. 2020 AMOUNT: $ 0. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 297880 74948 222932 216330 152240 64090 287022 LEASE DEPOSIT 15048 DUE FROM MAXAID 1395934 1410982 1 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 9108000 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 5366000 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 3547000 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 3143000 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 735000 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 694000 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 126000 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 76000 SOUTH ASIA 1 20 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 288000 EAST ASIA AND THE PACIFIC 2 9 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 251000 SUB-SAHARAN AFRICA 1 7 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 190000 SOUTH AMERICA 1 6 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 188000 NORTH AMERICA 0 2 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 65000 CENTRAL AMERICA AND THE CARIBBEAN 0 2 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 43000 RUSSIA AND NEIGHBORING STATES 0 2 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 43000 0 0 5 48 5 48 22795000 1068000 23863000 CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 33070 DIAGNOSTIC EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SOUTH ASIA DIAGNOSTIC TESTING 26200 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 25950 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 25000 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 22674 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 20463 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT RUSSIA AND NEIGHBOURING STATES DIAGNOSTIC TESTING 20000 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT EAST ASIA AND THE PACIFIC DIAGNOSTIC TESTING 17311 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SOUTH AMERICA DIAGNOSTIC TESTING 14815 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT RUSSIA AND NEIGHBOURING STATES DIAGNOSTIC TESTING 14000 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 12230 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 7975 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 7460 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT 13 0 DRUG SUB-SAHARAN AFRICA 9115 0 8982001 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EAST ASIA AND THE PACIFIC 742 5335863 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH ASIA 16345 1186 WIRE TRANSFER 3503636 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG RUSSIA AND NEIGHBORING STATES 3899 3106002 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH AMERICA 1243 726447 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG CENTRAL AMERICA AND THE CARIBBEAN 2103 598891 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG MIDDLE EAST AND NORTH AFRICA 87 125684 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EUROPE (INCLUDING ICELAND AND GREENLAND) 8 76090 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE 1 1 0 0 0 0 PART I, LINE 2: ALL GRANTS TO FOREIGN ENTITIES OR INDIVIDUALS ARE MADE SUBJECT TO A WRITTEN AGREEMENT OR AWARD LETTER THAT CLEARLY DEFINES DELIVERABLES. THE MAX FOUNDATION MAINTAINS A PROGRAM DATABASE IN ORDER TO TRACK DOCUMENTATION OF GRANT REQUESTS, QUALIFIED GRANTEES, AND FULFILLMENT OF GRANT REQUESTS. PROGRAM STAFF MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON THE ACCRUAL BASIS OF ACCOUNTING. PART III ACCOUNTING METHOD: PART IV, LINE 1 FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REPORTING REQUIREMENTS IN IRC SEC. 6038(A)(1)(A). 1 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N - PO BOX 19024 SEATTLE WA 98109 237156071 501(C)(3) 10000 SUPPORT FOR "SPOT ON" DIAGNOSTIC TESTING 1 0 PART I, LINE 2: ALL GRANTS TO US ENTITIES ARE MADE SUBJECT TO AN AWARD LETTER THAT CLEARLY DEFINES THE GRANTS SCOPE. PROGRAM TEAM MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. X X X 0 0 0 0 0 0 0 0 0 PATRICIA GARCIA-GONZALEZ CHIEF EXECUTIVE OFFICER 224270 0 10000 0 0 0 0 0 14560 0 248830 0 0 0 PATRICIA M PEARCE CHIEF FINANCIAL OFFICER 186964 0 0 0 0 0 0 0 12490 0 199454 0 0 0 INES GARCIA-GONZALEZ SEE PART V 55444 SEE PART V 0 SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: INES GARCIA GONZALEZ(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: FAMILY MEMBER OF PATRICIA GARCIA-GONZALEZ, CEO.(D) DESCRIPTION OF TRANSACTION: CONTRACTOR X 15000 DONOR VALUED X 2 12351 FAIR MARKET VALUE X 88312 5831785 HIGHEST COMM. VOL. X GIFT CARD 1 200 FACE VALUE 0 0 1 0 PART I, COLUMN (B): THE NUMBER IN COLUMN B LINE 20 REPRESENTS THE NUMBER OF TABS CONTRIBUTED, AND FOR ALL OTHER LINES IT REPRESENTS THE TOTAL CONTRIBUTIONS RECEIVED. FORM 990, PART I, LINE 6, VOLUNTEERS: THERE ARE EIGHT VOLUNTEER BOARD MEMBERS. PARTNER HEALTHCARE PROVIDERS VOLUNTEER THEIR TIME TO FULFILL ALL OBLIGATIONS RELATED TO PRESCRIBING, APPLYING FOR TREATMENT ACCESS REQUESTS ON BEHALF OF INDIVIDUAL PATIENTS, SUPPORT LOGISTICS AND OBTAINING IMPORT PERMITS FROM LOCAL HEALTHCARE AUTHORITIES, OVERSEE USE AND DISPENSATION OF DONATED PRODUCTS AND OTHER ACTIVITIES RELATED TO THEIR OBLIGATIONS WITHIN THE MAX ACCESS SOLUTIONS. IN 2020, THERE WERE 300 HEALTHCARE PROVIDERS IN OUR NETWORK. ADDITIONALLY, WE WORKED WITH 59 VOLUNTEERS TO ORGANIZE EDUCATION AND AWARENESS EVENTS. FORM 990, PART VI, SECTION B, LINE 11B THE TAX RETURN IS PREPARED BY AN OUTSIDE ACCOUNTANT. AFTER PREPARATION, THE FINANCE COMMITTEE PERFORMS A REVIEW OF THE RETURN. THE RETURN IS THEN FILED WITH THE IRS. A COPY IS PROVIDED TO THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD HAS ADOPTED A CONFLICT OF INTEREST POLICY AND THE POLICY IS REVIEWED ON AN ANNUAL BASIS. EACH YEAR, BOARD MEMBERS AND OFFICERS MUST REVIEW THE POLICY AND DETERMINE IF ANY CONFLICT OF INTERESTS EXIST. ANNUALLY, THE DISCLOSURES WERE REVIEWED BY THE EXECUTIVE ASSISTANT. SHOULD A CONFLICT ARISE, IT WOULD BE REVIEWED BY THE CFO, CEO AND BOARD TREASURER. NO BOARD MEMBER OR OFFICER MAY VOTE ON ANY MATTER UNDER CONSIDERATION IN WHICH SUCH PERSON HAS A CONFLICT OF INTEREST. FURTHER, ANY PERSON WITH A MATERIAL CONFLICT OF INTEREST IN ANY DECISION SHOULD BE ABSENT FROM THE ROOM DURING THE BOARD'S REVIEW, INCLUDING ITS VOTE, ON THE DECISION IN QUESTION. FORM 990, PART VI, SECTION B, LINE 15 THE CEO HAS A CONTRACT WITH THE BOARD, UPDATED AND APPROVED ON DECEMBER 19, 2019. IN THIS CONTRACT, A BASE SALARY AND A YEARLY PERCENTAGE INCREASE HAS BEEN ESTABLISHED, AS WELL AS A YEARLY BONUS. AN HR CONSULTANT, COMPENSATION ANALYSIS AND A WRITTEN PERFORMANCE EVALUATION ALL WENT INTO THE RENEWAL OF THE CEO CONTRACT DURING 2019. THE CFO WAS OFFICIALLY HIRED AS AN EMPLOYEE IN JULY 2018. BOTH THE CEO AND THE BOARD REVIEWED AND DETERMINED COMPENSATION. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART XII, LINE 2B AND PART IV LINE 12A ACTIVITY REPORTED ON THIS FORM 990 AND ITS AUDITED FINANCIAL STATEMENTS INCLUDES ALL ACTIVITY FOR ENTITIES REPORTED ON SCHEDULE R, PART IV AS WELL AS ALL BRANCH OFFICES AND LOCATIONS INCLUDING INDIA, THAILAND AND SOUTH AFRICA. MAXSTATION MALAYSIA SDN BHD UNIT 1302 LOBBY 1 BLOCK A DAMAN SELANGOR MY 320492996 PATIENT ORIENTED PROGRAMS MY 88765 29308 THE MAX FOUNDATION MAXAID 1107 NE 45TH NO 230 SEATTLE WA 98105 352577906 SUPPORT MAX FOUNDATION WA 501(C)(3) LINE 12A, I THE MAX FOUNDATION 1 THE MAX FOUNDATION SOUTH AFRICA TRUST 10 COSMOSPLACE DOORNPOORT PRETORIA SF 0186 TO SUPPORT MAX FOUNDATION SF MAX FOUNDATION T -8805 4728 1.00000 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 0 1 0 0 MAXAID L 3664669 BOOK